Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Qianhai Health Holdings's Enterprise Value is HK$28.0 Mil.
Qianhai Health Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$38.3 Mil. Therefore, Qianhai Health Holdings's EV-to-FCF for today is 0.73.
The historical rank and industry rank for Qianhai Health Holdings's EV-to-FCF or its related term are showing as below:
HKSE:00911'
s EV-to-FCF Range Over the Past 10 Years
Min: -32.44 Med: -0.63 Max: 56.87
Current: 1.11
During the past 13 years, the highest EV-to-FCF of Qianhai Health Holdings was 56.87. The lowest was -32.44. And the median was -0.63.
HKSE:00911's EV-to-FCF is ranked better than 96.25% of 560
companies
in the Drug Manufacturers industry
Industry Median: 21.44
vs HKSE:00911: 1.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qianhai Health Holdings (HKSE:00911) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qianhai Health Holdings's PE Ratio (TTM) for today is calculated as:
Qianhai Health Holdings's share price for today is HK$0.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Qianhai Health Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.035.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qianhai Health Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Qianhai Health Holdings's EV-to-FCF falls into.
Qianhai Health Holdings's current Enterprise Value is HK$28.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Qianhai Health Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$38.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qianhai Health Holdings (HKSE:00911) has a EV-to-FCF of 0.73 as of Aug. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qianhai Health Holdings and its competitors. According to the industry distribution chart, Qianhai Health Holdings ranks #21 out of 560 companies in the Drug Manufacturers industry, placing it in the top 3.7%.
Is Qianhai Health Holdings' EV-to-FCF too high?
Qianhai Health Holdings' current EV-to-FCF is 0.73. The Drug Manufacturers industry median EV-to-FCF is 21.44. Qianhai Health Holdings' value of 0.73 is 96.6% below this industry median. Based on the distribution chart, Qianhai Health Holdings ranks #21 out of 560 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #21 out of 560 companies for EV-to-FCF. This places Qianhai Health Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 21.44. Qianhai Health Holdings' value of 0.73 is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.44, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qianhai Health Holdings's current EV-to-FCF of 0.73 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qianhai Health Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qianhai Health Holdings's current EV-to-FCF is 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current EV-to-FCF is 0.73 and 96.6% below the Drug Manufacturers industry median of 21.44. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current EV-to-FCF is 0.73 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?
Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued.
The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22.
GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00911:
EV-to-FCF: 0.73
GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
Industry Position: 96.6% below the Drug Manufacturers median (#21 of 560)
No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score
Get the complete analysis for HKSE:00911
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00911 has been successfully added to your 
